Navigation Links
Actinobac Biomed Selected to Present at Cavendish Global Health Impact Forum

NEW BRUNSWICK, N.J., April 13, 2015 /PRNewswire-USNewswire/ -- Actinobac Biomed, Inc., a start-up biopharmaceutical company developing drugs to treat immune-related cancers and diseases, has been selected to present their findings and therapeutic technology at the Cavendish Global Health Impact Forum on May 10th to May 14th in La Jolla, California. 

The Forum's theme, a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World,' aims to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving and philanthropy programs within health and the life sciences. Presentations and panel discussions by leading research institutions, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment will be featured.  

"We are honored to be selected to present at this unique event and look forward to discussing our innovative approach to treat diseases that affect white blood cells which afflict millions of people around the world today," said Dr. Benjamin Belinka, president and CEO of Actinobac. "We welcome the chance to interact with many of the world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations which they are passionate about with other family offices from around the world.

"With the help of our expert advisors, we conducted a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence," explained Michael Moffat, Cavendish co-founder and chief executive officer.  "The quality and originality of Actinobac Biomed's research and scientific insights in the development of therapy that naturally targets and eliminates diseased white blood cells positions them to make a major contribution to the treatment of many life-threatening and debilitating diseases such as leukemia, lymphoma and autoimmune diseases."

About Actinobac Biomed, Inc.
Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases and HIV. Drug candidates are based on Leukothera®, a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Leukothera® functions by depleting and preventing migration of the activated immune cells involved in diseases of white blood cells. The cellular receptor for Leukothera™ is lymphocyte function associated antigen-1 (LFA-1). Since LFA-1 is expressed only on WBCs, other cells and tissues of the body are not affected.

More information is available at or by contacting Benjamin Belinka at

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted at leading research institutions of the community of La Jolla, California including The University of California San Diego, The J. Craig Venter Institute, The Scripps Research Institute, The Sanford-Burnham Medical Research Institute, The Sanford Consortium for Regenerative Medicine, and The Institute of the Americas.

For more information visit the website at or contact Alex Charlton, president, at or 917-576-1435.


SOURCE Actinobac Biomed, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
4. BioMed Realty Trust Declares First Quarter 2013 Common Stock Dividend
5. BioMed Realty To Lease 204,900 Square Feet To Life Technologies At The Science Center at Oyster Point In South San Francisco
6. Suspect Detection Systems Receives Funding From Israel-Publicly Traded Biomedix Ltd.
7. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
8. Start a Healthy Tradition this Earth Day: Tips from Topical BioMedics on How to Detox the Family Medicine Cabinet
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Premier Biomedical CEO Interviewed by The Wall Street Transcript
11. Oxford BioMedica Announces Update from ARVO 2013
Post Your Comments:
(Date:4/22/2020)... ... April 20, 2020 , ... Global ... announced today that Omixon’s founder and chairman Dr. Attila Berces returns as CEO. ... Holotype HLA since 2014 before stepping into the CEO role in 2017. ...
(Date:4/18/2020)... ... April 17, 2020 , ... ... (NSF) Small Business Innovation Research (SBIR) program to support the expansion of its ... from the NSF, which conducts a rigorous merit-based review process, adds to ...
(Date:4/1/2020)... (PRWEB) , ... March 30, 2020 , ... ... of its latest product, ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. As a ... biosecurity solution that provides continual antimicrobial activity against microorganisms for up to 90 ...
(Date:4/1/2020)... ... March 31, 2020 , ... Carterra® Inc., the world leader ... announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds of ... clinic as early as this summer. , La Jolla Institute for Immunology (LJI) ...
Breaking Biology Technology:
(Date:5/14/2020)... ... May 12, 2020 , ... ... helps Life Science Manufacturers accurately and easily project contracted liabilities with payers, ... Gross-to-Net models by projecting discounts/rebates to Commercial and Government entities, Copay and ...
(Date:5/6/2020)... LEXINGTON, Mass. (PRWEB) , ... May 06, 2020 , ... ... , a privately held medical technology company dedicated to improving the quality, safety, efficacy ... new partnership that will help SCDAA deliver on its mission and meet its goals. ...
(Date:5/1/2020)... ... April 30, 2020 , ... InBios International Inc., a leading ... been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), ... the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect ...
Breaking Biology News(10 mins):